<DOC>
	<DOCNO>NCT01622426</DOCNO>
	<brief_summary>The investigator aim assess tolerance new commercially available Aaf child affect IgE- non-IgE-mediated CMA .</brief_summary>
	<brief_title>Tolerance New Free Amino Acid-based Formula Children With IgE Non-IgE-mediated Cow 's Milk Allergy</brief_title>
	<detailed_description>Prospective control study include pediatric patient ( ≤14 year age ) recent diagnosis IgE- non-IgE-mediated CMA , confirm positive oral food challenge anaphylaxis 2 month prior enrollment good clinical control . Children concomitant chronic systemic disease , congenital cardiac defect , active tuberculosis , autoimmune disease , immunodeficiency , chronic inflammatory bowel disease , celiac disease , cystic fibrosis , metabolic disease , lactose intolerance , malignancy , chronic pulmonary disease , malformation gastrointestinal tract , gastroesophageal reflux disease non-food allergy-related , suspected eosinophilic gastrointestinal disorder , exclude . At first evaluation , clinical history , information allergic disease baseline clinical condition assess 3 experienced pediatric allergist child invite participate study . At least one parent subject provide write informed consent . Children atopic dermatitis include sufficient control allow recognition positive response challenge . Infants child use betablocker within 12 hour challenge , short-acting , medium-acting , long-acting antihistamine within 3 , 7 , 21 day DBPCFC , respectively , oral steroid within 21 day oral food challenge exclude study . Adverse event record throughout study . Food allergy screening test Measurement serum specific IgE CMP ( alpha-lactalbumin , ALA ; beta-lactoglobulin , BLG ; casein ) ; skin prick test ( SPT ) whole milk , CMP , placebo formula ( another commercially available Aaf , Neocate , Nutricia , Milan , Italy ) study formula ( Sineall , Humana , Milan , Italy ) ; atopy patch test ( APT ) whole milk , placebo study formula , perform patient . Serum sample patient analyse specific IgE antibody titer CMP use commercially available kit ( CAP-RAST , Pharmacia Diagnostics AB , Uppsala Sweden ) . The detection limit system 0.35 kU/L IgE . Subjects deem sensitised specific IgE level exceed detection limit . Skin prick test perform use 1-mm single peak lancet ( ALK , Copenhagen , Denmark ) , histamine dihydrochloride ( 10 mg/ml ) isotonic saline solution ( NaCl 0.9 % ) positive negative control , respectively . Reactions record basis large diameter ( millimetre ) wheal flare 15 min . The SPT result consider `` positive '' wheal 3 mm large , without reaction negative control . Atopy patch test perform previously report . Briefly , use 1 drop ( 50 μl ) fresh milk put filter paper apply adhesive tape unaffected skin child 's back , use 12-mm aluminium cup ( Finn Chambers Scan pore ; Epitest Ltd Oy , Tuusula , Finland ) . Isotonic saline solution negative control . The occlusion time 48 h result read 20 min 24 h removal cup . To exclude false positive reaction , also test allergen 1:10 solution . Seventy-two hour start test , reaction classify follow : - negative ; +/- doubtful : erythema ; + weak positive : erythema , slight infiltration , papule ; ++ strong positive : erythema , infiltration , papule , little vesicle ; +++ strong positive : erythema , large confluent vesicle bubble . Children family request report delay skin reaction notice time . Irritant doubtful reaction , include sharply demarcate confluent erythema , reaction confine margin without infiltration , deem negative . Oral food challenge All food challenge perform double blind placebo control food challenge ( DBPCFC ) manner , take place outpatient clinic 2 separate day one week interval , previously report . A 7-day period strict elimination CMP suspect food allergen precede DBPCFC . The result assess simultaneously 3 experience pediatric allergist center . Randomization preparation challenge perform clinical dietician directly involve study ; separate computer-generated randomization list participant number indicate order study formula offer DBPCFC challenge create . Briefly , every 20 minute , successive dos ( 0.1 , 0.3 , 1 , 3 , 10 , 30 100 mL ) placebo ( commercially available Aaf Neocate , Nutricia , Milan , Italy ) study formula ( Sineall , Humana , Milan , Italy ) administer . Full emergency equipment drug ( epinephrine , antihistamine , steroid ) hand . Study subject score nine item divide four main category ( general , skin , gastrointestinal , respiratory ) 0- 3-point scale ( 0 , none ; 1 , light ; 2 , moderate ; 3 , severe ) . If least two 3 specialist independently score item level 3 , 2 ( ) item level 2 , test result consider positive . The patient observe 2 h final dose , discharge . In case positive DBPCFC , test dose , patient remain observation symptom resolve . If patient show symptom within first 24 hour , assess long-term tolerance reveal false-negative result challenge , parent advise administer patient one single top dose test formula ( verum placebo ) everyday home seven day ( 7-day home feeding period ) . Participants ' parent record daily diary volume formula consume ; presence severity vomit , diarrhea , rash , runny nose , wheeze , symptom ( rat mild , moderate , excessive ) ; number bowel movement . If symptom occur period , patient return outpatient clinic day . The investigator complete final evaluation end 7-day home feeding period . After 7-day home feeding period verum placebo administration , patient examine parent interviewed Centers . To rule false-negative challenge result parent ask contact Center symptom occur follow 7 day DBPCFC procedure . The challenge consider negative patient tolerate entire challenge , include observation period.Markers intestinal mucosa inflammation The fecal concentration calprotectin ( FC ) eosinophilic cationic protein ( ECP ) determine 24 hour 7 14 day DBPCFC evaluate occurrence even subclinical intestinal mucosa inflammation response Aaf exposure . Stool sample collect , store -20°C analyze end study researcher blind result DBPCFC . Fecal calprotectin level measure highly sensitive enzyme-linked immunosorbent assay ( ELISA , Calprest® , Eurospital , Italy ) .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Milk Hypersensitivity</mesh_term>
	<criteria>Pediatric patient ( ≤14 year age ) recent diagnosis IgE nonIgEmediated CMA , confirm positive DBPCFC anaphylaxis 2 month prior enrollment good clinical control . Children concomitant chronic systemic disease Congenital cardiac defect Active tuberculosis Autoimmune diseases Immunodeficiency Chronic inflammatory bowel diseases Celiac disease Cystic fibrosis Metabolic diseases Lactose intolerance Malignancy Chronic pulmonary disease Malformations gastrointestinal tract Gastroesophageal reflux disease nonfood allergyrelated Suspected eosinophilic gastrointestinal disorder , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>168 Months</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>